BioStock

Prenumeration

Curasight’s eventful half-year crowned by EMA approval

2025-08-29 11:40:00

It has been an eventful year so far for Curasight. The company has completed a successful rights issue raising DKK 47 million, advanced its phase II prostate cancer trial with uTRACE, and strengthened the strategic investor base. But the most significant milestone came this August: the European Medicines Agency (EMA) approved the company’s clinical trial application for uTREAT, paving the way for its first therapeutic study in brain cancer.

Read the full article at biostock.se:

Curasight's eventful six months were crowned by EMA approval

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden